BLCO Stock Overview
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.65 |
| 52 Week High | US$21.95 |
| 52 Week Low | US$13.16 |
| Beta | 0.47 |
| 1 Month Change | 0.068% |
| 3 Month Change | 2.38% |
| 1 Year Change | -24.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.75% |
Recent News & Updates
Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30
Recent updates
Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
Nov 03An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued
Aug 15Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong
May 09Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate
Mar 28Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne
Feb 01Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Jan 24Bausch + Lomb acquires AcuFocus for cataract lens
Jan 17Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year
Dec 22Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops
Dec 13Bausch + Lomb: A Solid Play In Challenging Economic Times
Nov 09Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance range
Nov 02Shareholder Returns
| BLCO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.9% | 1.6% | 1.7% |
| 1Y | -24.7% | 1.8% | 26.3% |
Return vs Industry: BLCO underperformed the US Medical Equipment industry which returned 1.7% over the past year.
Return vs Market: BLCO underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| BLCO volatility | |
|---|---|
| BLCO Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BLCO has not had significant price volatility in the past 3 months.
Volatility Over Time: BLCO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,300 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Bausch + Lomb Corporation Fundamentals Summary
| BLCO fundamental statistics | |
|---|---|
| Market cap | US$5.15b |
| Earnings (TTM) | -US$337.00m |
| Revenue (TTM) | US$4.31b |
1.2x
P/S Ratio-15.3x
P/E RatioIs BLCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCO income statement (TTM) | |
|---|---|
| Revenue | US$4.31b |
| Cost of Revenue | US$1.69b |
| Gross Profit | US$2.62b |
| Other Expenses | US$2.96b |
| Earnings | -US$337.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 60.73% |
| Net Profit Margin | -7.81% |
| Debt/Equity Ratio | 68.1% |
How did BLCO perform over the long term?
See historical performance and comparison